-
Wellness for Everybody—in Every Body
In recent years, several qualitative studies have given us field notes of patients describing their experiences having larger bodies and interacting... -
Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacy Perspective on Insurance Coverage and Medication Access
Glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1s, have undoubtedly garnered much fanfare the past five years. This... -
My Journey with GLP-1 Weight Loss Drugs: Managing PCOS, Celiac Disease, and Metabolic Health
In my thirties, my body began to “betray” me. After years of running marathons, working out, and eating well, I found myself struggling with...
Archive
Perspectives in Primary Care features writing from practitioners, activists, and community members representing organizations, practices, and institutions across the United States and around the world.
Reference
Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacy Perspective on Insurance Coverage and Medication Access
Glucagon-like peptide-1 receptor agonists, more commonly referred to as GLP-1s, have undoubtedly garnered much fanfare the past five years. This class of medications is prescribed for many indications including diabetes, weight loss, and to reduce the risk of heart attack and stroke in adults with heart disease. The first GLP-1, Byetta (exenatide), was approved by the Food and Drug Administration (FDA) in 2005 to treat diabetes mellitus Type 2. It was not until 2014 that the first GLP-1 was ...
